PD-L1xVEGF Drug: 1st Global Data for SCLC from BioNTech
BioNTech and BMS reveal promising first global data for their new pd-l1xvegf drug, a novel bispecific antibody targeting Small Cell Lung Cancer (SCLC) patients.
oncology
Read More
new promising os trend: Summit’s Phase 3 global data
Explore the latest global data from Summit’s PD-1xVEGF clinical trial, revealing a new promising OS trend for patients. See how this breakthrough could change care.